Zum Inhalt springen

Nur-Lesen-Fassung: Das Forschungsinformationssystem (FIS) ist aus Sicherheitsgründen vorübergehend durch diese Nur-Lesen-Fassung ersetzt. Alle öffentlichen Inhalte und Volltexte sind weiterhin abrufbar; Anmeldung, Bearbeitung, Einreichung und Statistiken stehen nicht zur Verfügung. Bei Fragen: fis@uni-bamberg.de

Start › Publikationen › The German Fast Track Toward Reimbursement of Digital Health Applications (DiGA) : Opportunities and Challenges for Manufacturers, Healthcare Providers, and People With Diabetes

Publikation

The German Fast Track Toward Reimbursement of Digital Health Applications (DiGA) : Opportunities and Challenges for Manufacturers, Healthcare Providers, and People With Diabetes

Schliess, Freimut; Affini Dicenzo, Tatiana; Gaus, Nandor; u. a. (2022): The German Fast Track Toward Reimbursement of Digital Health Applications (DiGA) : Opportunities and Challenges for Manufacturers, Healthcare Providers, and People With Diabetes, in: Journal of Diabetes Science and Technology, London: Sage Publishing, Jg. 18, Nr. 2, S. 470–476, doi: 10.1177/19322968221121660.

Details

Fakultät/Lehrstuhl
Autorin(nen)/Autor(en)
Schliess, Freimut; Affini Dicenzo, Tatiana; Gaus, Nandor; Bourez, Jean-Marc; Stegbauer, Constance; Szecsenyi, Joachim; Jacobsen, Malte; Müller-Wieland, Dirk; Kulzer, Bernhard; Heinemann, Lutz
Titel der Zeitschrift
Journal of Diabetes Science and Technology
ISSN
1932-2968
Verlagsangabe
Sage Publishing : London
Erscheinungsjahr
2022
Jahrgang
18
Heft
2
Sprache(n)
Englisch
DOI
Abstract

Background: Digital health applications (DiGA) supporting the management of diabetes are among the most commonly available digital health technologies. However, transparent quality assurance of DiGA and clinical proof of a positive healthcare effect is often missing, which creates skepticism of some stakeholders regarding the usage and reimbursement of these applications.

Methods: This article reviews the recently established fast-track integration of DiGA in the German reimbursement market, with emphasis on the current impact for manufacturers, healthcare providers, and people with diabetes. The German DiGA fast track is contextualised with corresponding initiatives in Europe.

Results: The option of a provisional prescription and reimbursement of DiGA while proving a positive healthcare effect in parallel may expedite the adoption of DiGA in Germany and beyond. However, hurdles for a permanent prescription and reimbursement of DiGA are high and only one of 12 that have achieved this status specifically addresses people with diabetes.

Conclusion: The DiGA fast track needs to be further enhanced to cope with remaining skepticism and contribute even more to a value-based diabetes care.

Freie Schlagwort(e)
clinical trials
digital health
evidence
Germany
reimbursement
value-based healthcare
DDC-Klassifikation
150 Psychologie
RVK-Klassifikation
CU 3000
Peer Reviewed
ja
Internationale Verbreitung
ja
Open-Access-Zeitschrift
ja
Dokumenttyp
Artikel in einer Zeitschrift / Postprint
URI
Datum der Freischaltung
01.09.2025

Permalink: https://fis.uni-bamberg.de/handle/uniba/109985 · Daten als JSON · Zitieren: BibTeX · RIS

Datenstand: 16.11.2026

Eingeschränkter Lesezugriff: Anmeldung, Bearbeitung und Einreichung sind vorübergehend deaktiviert.